Profile: C R Bard Inc (BCR)
14 Dec 2017
C. R. Bard, Inc. (Bard), incorporated in 1923, is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. The Company sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company reports its sales in four product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. As of December 31, 2016, the Company, through its subsidiaries, marketed its products to customers in over 100 countries outside the United States. The Company's principal international markets are in Europe, Japan and China.
The Company's vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and end-stage renal disease (ESRD). These products include percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusion (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents and vascular grafts; vena cava filters, and biopsy devices. Bard's Conquest, Atlas and Dorado PTA catheters are used by clinicians for the treatment of arterial venous access stenosis and other PVDs. The Company's Ultraverse and VascuTrak PTA catheters, and Crosser CTO catheter are its offerings in the small-vessel segment of the PVD market. Bard's line of peripheral vascular stents, covered stents and vascular grafts includes the Flair arterial venous (AV) Access Stent Graft, E Luminexx and LifeStar Iliac Stents, and the LifeStent family of stents approved for use in the superficial femoral and proximal popliteal arteries.
The Company's vena cava filters product line includes devices that can be either permanently implanted or retrieved after the threat of blood clots traveling from the lower extremities to a patient's lungs has passed. Bard also offers products for the treatment of ESRD through a line of long-term dialysis catheters with products, including Equistream, Decathlon, Hickman and Reliance catheters. It offers a portfolio of automatic core needle biopsy devices, including MaxCore, Magnum, the Mission semi-automatic biopsy device and the Marquee disposable core biopsy instrument. Bard's Vacora and Finesse devices combine the benefits of a vacuum-assisted biopsy technology with a portable, self-contained needle system for the diagnosis of breast tumors. It offers a range of products across the percutaneous breast biopsy and tissue marker segments. The EnCor and EnCor Enspire breast biopsy systems allow for ultrasound, stereotactic and magnetic resonance imaging (MRI)-guided breast biopsy procedures, and Bard's breast tissue markers include the SenoMark, StarchMark, Gel Mark, UltraClip and UltraCor product line.
The Company's urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. The Foley catheter is the Company's product in the urology field. The Company markets Foley catheters, including the infection control (IC) Foley catheter (Bardex I.C. Foley catheter), for the treatment of urinary tract infections. Other products include fecal incontinence products; brachytherapy devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents, and specialty devices for stone removal procedures. The Company also markets the line of StatLock catheter stabilization devices, which are used primarily to secure peripheral intravenous catheters. These devices are also used to secure other types of catheters sold by Bard and other companies, including Foley catheters. In addition, the Company markets the Arctic Sun system with ArcticGel pads providing therapy for patients requiring Targeted Temperature Management.
The Company's oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. Bard's oncology business includes specialty vascular access products and enteral feeding devices. Specialty vascular access products include peripherally inserted central catheters (PICCs) used for intermediate to long-term central venous access, specialty access ports and accessories (Ports) used commonly for chemotherapy, dialysis access catheters and vascular access ultrasound devices, which help facilitate the placement of PICCs. Its PowerPICC catheters and PowerPort devices can also be used to inject contrast media at high flow rates. Bard's Site-Rite vascular access ultrasound device and Sherlock tip locator system help nurses place a PICC at a patient's bedside. The Company's 3CG Tip Confirmation System can be used in place of imaging technologies, such as x-rays to confirm proper placement of the PICC prior to treatment. Both Sherlock and Sherlock 3CG can be integrated into the Site Rite system facilitating bedside placement. For patients not requiring central venous access, Bard offers a range of midline catheters, as well as guidewire-assisted peripheral intravenous lines.
Surgical Specialty Products
The Company's surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs, in addition to hemostats and surgical sealants. The Company's soft tissue repair products consist of hernia repair grafts, including permanent synthetic and bioresorbable synthetic products, natural-tissue configurations and hernia fixation devices. Bard has a line of products for inguinal (groin) hernias, including the Perfix Plug and 3D Max product lines. The Company has products for the repair of ventral (abdominal) hernias, including the Ventrio, Ventrio ST, Ventralex, Ventralex ST and Ventralight ST synthetic grafts. In addition, it markets the ECHO PS Positioning System, which helps facilitate mesh deployment in laparoscopic surgical repair. Bard also markets the Phasix line of products for both inguinal and ventral hernias. Bard's line of natural-tissue products includes the XenMatrix and Allomax grafts used to repair ventral hernias and soft tissue reconstruction. The Company's hernia fixation devices include OptiFix, a bioresorbable-tack fixation device, and Capsure, a permanent fixation device for use in laparoscopic and open surgical procedures. Bard also offers the Progel surgical sealant, which is available for intraoperative sealing of air leaks in connection with open, video-assisted and robotic thoracic surgery.
C R Bard Inc
730 Central Ave
NEW PROVIDENCE NJ 07974-1139
Company Web Links
- BRIEF-BD announces extension of exchange offers and consent solicitations for C. R. Bard, Inc.
- BRIEF-C R Bard reports Q3 earnings per share $1.25
- Becton Dickinson wins conditional EU approval for $24 billion Bard buy
- Becton Dickinson wins conditional EU approval for $24 bln Bard buy
- BRIEF-BD extends exchange offers and consent solicitations for C R Bard Inc notes